Developer docs
API playgroundTry for free, no card

Search company profiles

Antiva Biosciences

Full company profile

uuid0002z7j

Namestring
Antiva Biosciences
Legal namestring
Antiva Biosciences, Inc.
Websiteurl
antivabio.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Antiva Biosciences is a clinical-stage biopharmaceutical company founded in 2012 by Dr. Karl Hostetler at UC San Diego (originally as Hera Therapeutics) and headquartered in Redwood City, California. The company develops novel topical therapeutics targeting oncogenic (high-risk) human papillomavirus (HPV) infections and pre-cancerous cervical lesions (CIN 2,3), indications for which no FDA-approved drug treatment currently exists. Its lead product, ABI-2280, is an acyclic nucleoside phosphonate prodrug of PMEG diphosphate formulated as an intravaginal insert for at-home self-administration; the drug inhibits human intracellular DNA polymerases used by all HPV genotypes, blocking viral replication and inducing apoptosis in HPV-infected cells while sparing normal cells.

ABI-2280 is being evaluated in two parallel Phase 1/2 programs: one in women with persistent cervical high-risk HPV infection and one in CIN 2,3 patients. Phase 1b/2 results announced in August 2025 and presented at SGO 2026 showed 46% hrHPV negativity at Week 12 vs 16% placebo (p=0.0077), 78% HPV16+ clearance vs 0% placebo, and durable response in 100% of Week 12 responders at Week 24. The product's broad-spectrum, immune-independent mechanism is intended to treat all HPV genotypes and remain effective in immunocompromised (e.g., HIV-positive) women.

Antiva has raised approximately $137 million in venture financing across Series B through E (2015-2023), with a $53 million Series E led by MPM-BioImpact Capital in April 2023. Lead institutional investors include Canaan Partners, Sofinnova, Brace Pharma, Hillhouse, Adjuvant Capital, GV, HBM Healthcare, and Lumira Ventures. The business model is standard biopharmaceutical prescription sales of ABI-2280 through OB/GYN prescribing channels and retail/specialty pharmacy distribution upon FDA approval, with an additional global health strategy targeting women in lower- and middle-income countries where cervical cancer mortality is highest. The company is led by President & CEO Kristine Ball (appointed April 2023), with a Scientific and Development Advisory Board comprising virology and women's health leaders including former Gilead R&D executives and ASCCP-recognized clinicians.

Short descriptiontext

Antiva Biosciences is a clinical-stage biopharmaceutical company developing ABI-2280, a topical, self-administered antiviral therapeutic for high-risk HPV infection and cervical pre-cancerous lesions (CIN 2,3), serving women with persistent hrHPV.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
HPV therapeutics, cervical cancer treatment, topical antivirals, biopharmaceutical research, antiviral prodrugs
Industry1 code
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Antiviral Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1ABI-2280 Pharmaceutical Sales
TypeOne Time License
Description

Once approved, the company will generate revenue through prescription pharmaceutical sales of ABI-2280 vaginal insert for treatment of high-risk HPV infection and CIN 2,3. As a topical therapeutic prescribed by physicians and self-administered by patients, revenue model will involve standard pharmaceutical distribution channels.

antivabio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Antiva Biosciences is developing ABI-2280, a novel topical therapeutic (acyclic nucleoside phosphonate prodrug) for the treatment of oncogenic (high-risk) HPV infection and pre-cancerous cervical lesions (CIN 2,3). The drug is formulated as an intravaginal insert for self-administration at home, designed to block HPV replication and induce apoptosis in HPV-infected cells while sparing normal cells.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 46% of patients achieved hrHPV negativity at Week 12 with 3mg cumulative dose vs 16% for placebo (p=0.0077)
+5 more records
Product overview1 text field

Antiva Biosciences is developing a single lead product, ABI-2280, a novel topical therapeutic using antiviral prodrug chemistry developed by Dr. Karl Hostetler at UC San Diego. ABI-2280 is an acyclic nucleoside phosphonate prodrug of PMEG diphosphate formulated as an intravaginal insert for patient self-administration. The product is being developed for two indications: high-risk cervical HPV infection and CIN 2,3 (cervical intraepithelial neoplasia). The company has completed a Phase 1b/2 study in women with persistent high-risk HPV infection achieving statistically significant results, and has an ongoing open-label Phase 1b/2 study in CIN 2,3 patients. No other distinct products or modules are in the portfolio.

Product and service1 record
1ABI-2280
CategoryAntiviral Therapeutics
Description

A novel topical therapeutic (acyclic nucleoside phosphonate prodrug of PMEG diphosphate) for treatment of high-risk HPV infection and pre-cancerous moderate to high-grade cervical intraepithelial neoplasias (CIN 2,3). Formulated as an intravaginal insert for self-administration at home, targeting women diagnosed with persistent high-risk HPV infection or CIN 2,3 lesions.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Pfizer markets broad women's health and oncology assets and historically participated in HPV vaccine commercialization through legacy Wyeth operations. It is a relevant broad incumbent and potential strategic acquirer in cervical cancer therapeutics.

TypeDirect peer
Description

Inovio is a clinical-stage biotech developing DNA-based immunotherapies for HPV-related diseases, including INO-3107 for HPV-6/11-related recurrent respiratory papillomatosis and HPV-associated cervical dysplasia. It is the closest direct comparable to Antiva's therapeutic HPV approach, competing for the same underserved patient population.

TypeDirect peer
Description

ISA Pharmaceuticals is a clinical-stage biotech developing synthetic long-peptide immunotherapy (ISA101) for HPV16-driven cancers and pre-cancers. It is a direct peer in therapeutic HPV oncology and shares Antiva's positioning in CIN/anal pre-cancer.

TypeBroad incumbent
Description

GSK markets Cervarix, the second major prophylactic HPV vaccine, alongside a broader women's health and oncology portfolio. Like Merck, GSK shapes the HPV disease landscape through preventive vaccination and represents a relevant strategic acquirer or global commercial partner for ABI-2280.

5PapiVax Biotech
TypeDirect peer
Description

PapiVax is a clinical-stage biotech developing therapeutic HPV vaccines and immunotherapies, including candidates targeting cervical pre-cancer (CIN) and other HPV-driven lesions. It is one of the few small, dedicated players in therapeutic HPV alongside Antiva.

TypeBroad incumbent
Description

Merck markets Gardasil, the leading prophylactic HPV vaccine, and Keytruda, approved for certain HPV-associated cancers. While its vaccines are preventive rather than therapeutic, Merck defines the broader HPV/cervical-cancer category and represents both a major indirect competitor and a potential acquirer of Antiva's asset.

TypeBroad incumbent
Description

Roche is the leader in cervical cancer diagnostics (cobas HPV test) and markets several cervical/gynecologic oncology therapeutics. Its dominant position in HPV screening positions it as both an indirect competitor and a natural commercial partner given ABI-2280's reliance on HPV-positive patient identification.

8Bristol Myers Squibb
TypeBroad incumbent
Description

BMS markets Opdivo, approved for certain cervical cancer indications, and has a deep immuno-oncology and antivirals heritage. It is a broad incumbent in HPV-associated cancer treatment and a credible strategic acquirer for late-stage cervical assets.

TypeDirect peer
Description

Advaxis pioneered Lm-LLO immunotherapy for HPV-associated cancers; its work has been continued through Ayala Pharmaceuticals. It represents a direct peer in the therapeutic HPV oncology space, with similar clinical-stage positioning.

10Eisai Co.
TypeBroad incumbent
Description

Eisai co-markets Lenvima (lenvatinib), approved in combination for certain advanced cervical cancer settings. While a broader oncology player, Eisai's involvement in HPV-related cervical cancer treatment makes it a relevant comparable and potential global commercial partner for ABI-2280.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Antiva Biosciences

Antiviral Therapeuticsantivabio.com

Antiva Biosciences is a clinical-stage biopharmaceutical company developing ABI-2280, a topical, self-administered antiviral therapeutic for high-risk HPV infection and cervical pre-cancerous lesions (CIN 2,3), serving women with persistent hrHPV.

What Antiva Biosciences does

Antiva Biosciences is a clinical-stage biopharmaceutical company founded in 2012 by Dr. Karl Hostetler at UC San Diego (originally as Hera Therapeutics) and headquartered in Redwood City, California. The company develops novel topical therapeutics targeting oncogenic (high-risk) human papillomavirus (HPV) infections and pre-cancerous cervical lesions (CIN 2,3), indications for which no FDA-approved drug treatment currently exists. Its lead product, ABI-2280, is an acyclic nucleoside phosphonate prodrug of PMEG diphosphate formulated as an intravaginal insert for at-home self-administration; the drug inhibits human intracellular DNA polymerases used by all HPV genotypes, blocking viral replication and inducing apoptosis in HPV-infected cells while sparing normal cells.

ABI-2280 is being evaluated in two parallel Phase 1/2 programs: one in women with persistent cervical high-risk HPV infection and one in CIN 2,3 patients. Phase 1b/2 results announced in August 2025 and presented at SGO 2026 showed 46% hrHPV negativity at Week 12 vs 16% placebo (p=0.0077), 78% HPV16+ clearance vs 0% placebo, and durable response in 100% of Week 12 responders at Week 24. The product's broad-spectrum, immune-independent mechanism is intended to treat all HPV genotypes and remain effective in immunocompromised (e.g., HIV-positive) women.

Antiva has raised approximately $137 million in venture financing across Series B through E (2015-2023), with a $53 million Series E led by MPM-BioImpact Capital in April 2023. Lead institutional investors include Canaan Partners, Sofinnova, Brace Pharma, Hillhouse, Adjuvant Capital, GV, HBM Healthcare, and Lumira Ventures. The business model is standard biopharmaceutical prescription sales of ABI-2280 through OB/GYN prescribing channels and retail/specialty pharmacy distribution upon FDA approval, with an additional global health strategy targeting women in lower- and middle-income countries where cervical cancer mortality is highest. The company is led by President & CEO Kristine Ball (appointed April 2023), with a Scientific and Development Advisory Board comprising virology and women's health leaders including former Gilead R&D executives and ASCCP-recognized clinicians.

Antiva Biosciences firmographics

Firmographics
Name
Antiva Biosciences
Legal name
Antiva Biosciences, Inc.
Website
https://antivabio.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Antiva Biosciences is a clinical-stage biopharmaceutical company developing ABI-2280, a topical, self-administered antiviral therapeutic for high-risk HPV infection and cervical pre-cancerous lesions (CIN 2,3), serving women with persistent hrHPV.
Ownership category
akta.pro rank

Antiva Biosciences industry classification

Industry
Product category
Antiviral Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • HPV therapeutics
  • Cervical cancer treatment
  • Topical antivirals
  • Biopharmaceutical research
  • Antiviral prodrugs

Where Antiva Biosciences is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Antiva Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. ABI-2280 Pharmaceutical Sales: Once approved, the company will generate revenue through prescription pharmaceutical sales of ABI-2280 vaginal insert for treatment of high-risk HPV infection and CIN 2,3. As a topical therapeutic prescribed by physicians and self-administered by patients, revenue model will involve standard pharmaceutical distribution channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Antiva Biosciences product offering

Product offering

Core offering

Antiva Biosciences is developing ABI-2280, a novel topical therapeutic (acyclic nucleoside phosphonate prodrug) for the treatment of oncogenic (high-risk) HPV infection and pre-cancerous cervical lesions (CIN 2,3). The drug is formulated as an intravaginal insert for self-administration at home, designed to block HPV replication and induce apoptosis in HPV-infected cells while sparing normal cells.

Product overview

Antiva Biosciences is developing a single lead product, ABI-2280, a novel topical therapeutic using antiviral prodrug chemistry developed by Dr. Karl Hostetler at UC San Diego. ABI-2280 is an acyclic nucleoside phosphonate prodrug of PMEG diphosphate formulated as an intravaginal insert for patient self-administration. The product is being developed for two indications: high-risk cervical HPV infection and CIN 2,3 (cervical intraepithelial neoplasia). The company has completed a Phase 1b/2 study in women with persistent high-risk HPV infection achieving statistically significant results, and has an ongoing open-label Phase 1b/2 study in CIN 2,3 patients. No other distinct products or modules are in the portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • ABI-2280 A novel topical therapeutic (acyclic nucleoside phosphonate prodrug of PMEG diphosphate) for treatment of high-risk HPV infection and pre-cancerous moderate to high-grade cervical intraepithelial neoplasias (CIN 2,3). Formulated as an intravaginal insert for self-administration at home, targeting women diagnosed with persistent high-risk HPV infection or CIN 2,3 lesions.

Quantifiable outcome

  • 46% of patients achieved hrHPV negativity at Week 12 with 3mg cumulative dose vs 16% for placebo (p=0.0077)
  • +5 more outcomes

Companies that use Antiva Biosciences

Customer profile

Segments3 records

Ideal customer profiles3 records

Antiva Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Antiva Biosciences partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Antiva Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Pfizer markets broad women's health and oncology assets and historically participated in HPV vaccine commercialization through legacy Wyeth operations. It is a relevant broad incumbent and potential strategic acquirer in cervical cancer therapeutics.
  • GSK: GSK markets Cervarix, the second major prophylactic HPV vaccine, alongside a broader women's health and oncology portfolio. Like Merck, GSK shapes the HPV disease landscape through preventive vaccination and represents a relevant strategic acquirer or global commercial partner for ABI-2280.
  • Merck & Co. Merck markets Gardasil, the leading prophylactic HPV vaccine, and Keytruda, approved for certain HPV-associated cancers. While its vaccines are preventive rather than therapeutic, Merck defines the broader HPV/cervical-cancer category and represents both a major indirect competitor and a potential acquirer of Antiva's asset.
  • Roche: Roche is the leader in cervical cancer diagnostics (cobas HPV test) and markets several cervical/gynecologic oncology therapeutics. Its dominant position in HPV screening positions it as both an indirect competitor and a natural commercial partner given ABI-2280's reliance on HPV-positive patient identification.
  • Bristol Myers Squibb: BMS markets Opdivo, approved for certain cervical cancer indications, and has a deep immuno-oncology and antivirals heritage. It is a broad incumbent in HPV-associated cancer treatment and a credible strategic acquirer for late-stage cervical assets.
  • Eisai Co. Eisai co-markets Lenvima (lenvatinib), approved in combination for certain advanced cervical cancer settings. While a broader oncology player, Eisai's involvement in HPV-related cervical cancer treatment makes it a relevant comparable and potential global commercial partner for ABI-2280.

Direct peers

  • Inovio Pharmaceuticals: Inovio is a clinical-stage biotech developing DNA-based immunotherapies for HPV-related diseases, including INO-3107 for HPV-6/11-related recurrent respiratory papillomatosis and HPV-associated cervical dysplasia. It is the closest direct comparable to Antiva's therapeutic HPV approach, competing for the same underserved patient population.
  • ISA Pharmaceuticals: ISA Pharmaceuticals is a clinical-stage biotech developing synthetic long-peptide immunotherapy (ISA101) for HPV16-driven cancers and pre-cancers. It is a direct peer in therapeutic HPV oncology and shares Antiva's positioning in CIN/anal pre-cancer.
  • PapiVax Biotech: PapiVax is a clinical-stage biotech developing therapeutic HPV vaccines and immunotherapies, including candidates targeting cervical pre-cancer (CIN) and other HPV-driven lesions. It is one of the few small, dedicated players in therapeutic HPV alongside Antiva.
  • Advaxis (now Ayala Pharmaceuticals): Advaxis pioneered Lm-LLO immunotherapy for HPV-associated cancers; its work has been continued through Ayala Pharmaceuticals. It represents a direct peer in the therapeutic HPV oncology space, with similar clinical-stage positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Antiva Biosciences social profiles

Digital presence

Antiva Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Antiva Biosciences leadership team

Management profile

Number of profiles

Profiles8 records

Antiva Biosciences funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Antiva Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antiva Biosciences

What does Antiva Biosciences do?

Antiva Biosciences is developing ABI-2280, a novel topical therapeutic (acyclic nucleoside phosphonate prodrug) for the treatment of oncogenic (high-risk) HPV infection and pre-cancerous cervical lesions (CIN 2,3). The drug is formulated as an intravaginal insert for self-administration at home, designed to block HPV replication and induce apoptosis in HPV-infected cells while sparing normal cells.

Is Antiva Biosciences a public or private company?

Antiva Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Antiva Biosciences founded?

Antiva Biosciences was founded in 2012. It employs 11 to 50 people.

Where is Antiva Biosciences based?

Antiva Biosciences is headquartered in South San Francisco, United States, in the North America region.

How does Antiva Biosciences make money?

One revenue line is on record: ABI-2280 Pharmaceutical Sales.

Who are Antiva Biosciences's main competitors?

Broad incumbents on record are Pfizer, GSK, Merck & Co., Roche, Bristol Myers Squibb and Eisai Co.. Direct peers are Inovio Pharmaceuticals, ISA Pharmaceuticals, PapiVax Biotech and Advaxis (now Ayala Pharmaceuticals).

Does Antiva Biosciences have an API?

No public API is recorded for Antiva Biosciences.

What industry is Antiva Biosciences in?

Antiva Biosciences's product category is Antiviral Therapeutics. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceAntiva Biosciences Presents Data from Phase 1b/2 Study of ABI-2280 for Treatment of Cervical High-Risk HPV Infection at SGO 2026Antiva Biosciences presented Phase 1b/2 trial data for ABI-2280 at SGO 2026, showing 46% hrHPV negativity at Week 12 versus 16% placebo. In HPV16+ patients, 78% achieved HPV16 negativity at Week 12, with 100% of Week 12 responders maintaining negativity at Week 24. The company plans to advance to a Phase 2b trial.Business Wire BlogAntiva Biosciences Presents Data from Phase 1b/2 Study of ABI-2280 for Treatment of Cervical High-Risk HPV Infection at SGO 2026Antiva Biosciences presented positive Phase 1b/2 clinical trial data for its drug candidate ABI-2280, showing it achieved primary and secondary endpoints in treating persistent high-risk cervical HPV infection. The treatment demonstrated statistically significant viral clearance rates compared to placebo, with 78% of patients with the HPV16 genotype achieving negativity at Week 12. Antiva intends to advance this therapy into a Phase 2b trial following recent FDA clearance of its Investigational New Drug application.PR NewswireAntiva Biosciences Announces Positive Top-Line Results from Phase 1b/2 Study of ABI-2280 for Treatment of Cervical High-Risk Human Papillomavirus (hrHPV) InfectionAntiva Biosciences announced positive top-line results from its Phase 1b/2 clinical trial of ABI-2280 for treating cervical high-risk HPV infection, with 46% of patients in the 3mg cohort achieving hrHPV negativity at Week 12 versus 16% for placebo, meeting the primary endpoint with statistical significance (p=0.0077). Interim Week 24 data showed durability of response, with 87% of Week 12 responders maintaining hrHPV negativity, and the treatment demonstrated a favorable safety profile with mild-to-moderate adverse events localized to the treatment area. The company plans to advance ABI-2280 into a Phase 2b trial based on these results, addressing a significant unmet medical need as there are currently no approved therapeutic options for persistent hrHPV infections.BioSpaceAntiva Biosciences Announces Formation of Scientific and Development Advisory BoardAntiva Biosciences announced the formation of a scientific and development advisory board to provide strategic guidance for its lead drug candidate, ABI-2280. The board comprises experts in virology and women's health who will assist in developing the topical treatment for high-grade cervical intraepithelial neoplasia and high-risk HPV infection.PR NewswireCervical Intraepithelial Neoplasia Pipeline Research Report 2023 Featuring Inovio Pharmaceuticals, Frantz Viral Therapeutics, Antiva Biosciences, Genexine, and Merck Sharp & DohmeResearchAndMarkets.com published a clinical trials report covering the Cervical Intraepithelial Neoplasia (CIN) pipeline, identifying more than 8 companies developing over 10 pipeline drugs across various clinical stages. Key drug candidates include VGX-3100 from Inovio Pharmaceuticals (Phase III), Artesunate from Frantz Viral Therapeutics (Phase II), as well as ABI-2280, GX-188E, and Pembrolizumab from other developers. The report provides therapeutic assessments, development activities, and product profiles for emerging CIN treatments targeting precancerous cervical dysplasia.PR NewswireAntiva Biosciences Strengthens Leadership with Key New AppointmentsAntiva Biosciences appointed Elaine Chien as chief medical officer, Susan Wilson as vice president of project management, and Rajashree Joshi-Hangal as vice president of technical operations. The appointments aim to support advancing its lead candidate ABI-2280 into Phase 2a trials for high-grade cervical intraepithelial neoplasia and high-risk HPV infection.SecSEC FORM DThe Securities and Exchange Commission facilitated the filing of a Notice of Exempt Offering of Securities by Antiva Biosciences, Inc. reporting a total offering amount of $52,999,990 USD. The offering is set to last no more than one year, and as of the filing date, $26,565,771 USD has been sold with $26,434,219 USD remaining.Venture Capital Access OnlineAntiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEOAntiva Biosciences closed a $53 million Series E equity financing led by MPM-BioImpact Capital to fund the advancement of its lead drug candidate, ABI-2280, into Phase 2 clinical trials for high-grade cervical intraepithelial neoplasia. Concurrently, Kristine Ball succeeded Gail Maderis as President and CEO, with several new board members joining from the lead investor firm. The proceeds will support key efficacy studies through late 2025, aiming to address the unmet medical need for treatments that resolve persistent high-risk HPV infections.AntivabioAntiva Press ReleaseAntiva Biosciences closed a $53 million Series E equity financing led by MPM-BioImpact Capital to fund clinical development of its lead candidate, ABI-2280. Concurrently, Kristine Ball succeeded Gail Maderis as President and CEO, with several investors joining the board. The proceeds will support Phase 2 trials for high-grade cervical intraepithelial neoplasia and exploratory studies for high-risk HPV infections.